The estimated Net Worth of Jotin Marango is at least $1.48 Million dollars as of 10 July 2020. Jotin Marango owns over 62,835 units of Aptose Biosciences Inc stock worth over $42,885 and over the last 5 years he sold APTO stock worth over $512,949. In addition, he makes $928,459 as Senior Vice President and Chief Business Officer at Aptose Biosciences Inc.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Sign up
Jotin Marango APTO stock SEC Form 4 insiders trading
Jotin has made over 2 trades of the Aptose Biosciences Inc stock since 2020, according to the Form 4 filled with the SEC. Most recently he sold 62,835 units of APTO stock worth $380,152 on 10 July 2020.
The largest trade he's ever made was selling 62,835 units of Aptose Biosciences Inc stock on 10 July 2020 worth over $380,152. On average, Jotin trades about 10,473 units every 1 days since 2019. As of 10 July 2020 he still owns at least 116,219 units of Aptose Biosciences Inc stock.
You can see the complete history of Jotin Marango stock trades at the bottom of the page.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Jotin Marango biography
Dr. Jotin Marango M.D., Ph.D. serves as Senior Vice President, Chief Business Officer of the Company. serves as Senior Vice President, Chief Business Officer of the Company. is Senior Vice President, Chief Business Officer of the Company. Prior to joining Aptose, from 2017 to 2019, Dr. Marango was a managing director and senior research analyst at Roth Capital Partners covering biotechnology and therapeutics. Dr. Marango joined Roth from H.C. Wainwright & Co., where he worked from 2015 to 2017 and covered hematology, oncology, and pulmonary therapeutics, with a focus on epigenetic and molecularly targeted therapies. Dr. Marango began his career in equity research with Collins Stewart/Canaccord Genuity in 2010. Previously, Dr. Marango also served as Chief Operating Officer at the Samuel Waxman Cancer Research Foundation from 2012 to 2015, where he oversaw academic collaborations in translational therapeutics, as well as venture philanthropy initiatives in drug development. Dr. Marango studied theoretical chemistry and classical literature at Harvard University and later received his M.D. and Ph.D. degrees from the Mount Sinai School of Medicine in New York.
What is the salary of Jotin Marango?
As the Senior Vice President and Chief Business Officer of Aptose Biosciences Inc, the total compensation of Jotin Marango at Aptose Biosciences Inc is $928,459. There are 2 executives at Aptose Biosciences Inc getting paid more, with William Rice having the highest compensation of $1,511,900.
How old is Jotin Marango?
Jotin Marango is 41, he's been the Senior Vice President and Chief Business Officer of Aptose Biosciences Inc since 2019. There are 12 older and no younger executives at Aptose Biosciences Inc. The oldest executive at Aptose Biosciences Inc is Denis Burger, 75, who is the Lead Independent Director.
What's Jotin Marango's mailing address?
Jotin's mailing address filed with the SEC is C/O APTOSE BIOSCIENCES INC., 251 CONSUMERS ROAD, SUITE 1105, TORONTO, A6, M2J 4R3.
Insiders trading at Aptose Biosciences Inc
Over the last 6 years, insiders at Aptose Biosciences Inc have traded over $2,827,381 worth of Aptose Biosciences Inc stock and bought 538,629 units worth $767,189 . The most active insiders traders include Erich Platzer, Bernd R. Seizinger, and William G. Rice. On average, Aptose Biosciences Inc executives and independent directors trade stock every 59 days with the average trade being worth of $14,277. The most recent stock trade was executed by Bernd R. Seizinger on 22 September 2023, trading 17,000 units of APTO stock currently worth $53,380.
What does Aptose Biosciences Inc do?
aptose biosciences is a science-driven biotechnology company advancing first-in-class agents to treat life-threatening cancers, such as acute myeloid leukemia (aml), high-risk myelodysplastic syndromes (mds) and other hematologic malignancies. based on insights into the genetic and epigenetic profiles of certain cancers and patient populations, aptose is building a pipeline of novel oncology therapies directed at dysregulated processes and signaling pathways. aptose is developing targeted medicines for precision treatment of these diseases, based on a patient’s specific gene expression signature. in the treatment of cancer, this strategy is intended to optimize efficacy and quality of life by minimizing the cytotoxic side effects associated with conventional therapies. cg026806 (cg’806) is a highly potent first-in-class pan-flt3/btk inhibitor. this small molecule therapeutic agent, exhibits a picomolar ic50 toward the fms-like tyrosine kinase 3 with the internal tandem duplication (flt
What does Aptose Biosciences Inc's logo look like?
Complete history of Jotin Marango stock trades at Aptose Biosciences Inc
Aptose Biosciences Inc executives and stock owners
Aptose Biosciences Inc executives and other stock owners filed with the SEC include:
-
William Rice,
Chairman of the Board, President, Chief Executive Officer -
Gregory Chow,
Chief Financial Officer, Executive Vice President -
Jotin Marango,
Senior Vice President, Chief Business Officer -
Dr. William G. Rice Ph.D.,
Chairman, Pres & CEO -
Dr. Jotin Marango Ph.D., M.D.,
Sr. VP, CFO, Chief Accounting Officer & Chief Bus. Officer -
Dr. Rafael Bejar M.D., Ph.D.,
Sr. VP & Chief Medical Officer -
Denis Burger,
Lead Independent Director -
Caroline Loewy,
Independent Director -
Carol Ashe,
Independent Director -
Warren Whitehead,
Independent Director -
Mark Vincent,
Independent Director -
Erich Platzer,
Independent Director -
Rafael Bejar,
Senior Vice President, Chief Medical Officer -
Roger Davies B.Sc.,
VP of Operations -
Bernd R. Seizinger,
-
Fletcher Payne,
Sr VP and CFO -
Philippe Ledru,